CVS Health Corporation (NYSE:CVS)‘s stock had its “outperform” rating reissued by Credit Suisse Group AG in a note issued to investors on Tuesday. They presently have a $110.00 price target on the pharmacy operator’s stock, down from their previous price target of $115.00. Credit Suisse Group AG’s price target suggests a potential upside of 26.31% from the company’s current price.

Several other research firms have also recently commented on CVS. Morgan Stanley restated a “hold” rating and issued a $104.00 target price on shares of CVS Health Corporation in a research report on Wednesday, August 3rd. Jefferies Group reiterated a “buy” rating on shares of CVS Health Corporation in a report on Monday, July 4th. FBR & Co reiterated an “outperform” rating and issued a $120.00 price objective on shares of CVS Health Corporation in a report on Wednesday, August 3rd. Deutsche Bank AG increased their price objective on shares of CVS Health Corporation from $99.00 to $108.00 and gave the company a “hold” rating in a report on Wednesday, August 3rd. Finally, Mizuho reiterated a “buy” rating and issued a $108.00 price objective (down from $117.00) on shares of CVS Health Corporation in a report on Thursday, June 23rd. Six equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. CVS Health Corporation currently has a consensus rating of “Buy” and a consensus price target of $112.44.

CVS Health Corporation (NYSE:CVS) traded down 0.18% during mid-day trading on Tuesday, reaching $86.93. 1,215,066 shares of the company’s stock traded hands. The company has a 50-day moving average of $92.69 and a 200-day moving average of $97.29. CVS Health Corporation has a 52-week low of $86.50 and a 52-week high of $106.67. The company has a market capitalization of $92.69 billion, a price-to-earnings ratio of 20.00 and a beta of 0.83.

CVS Health Corporation (NYSE:CVS) last posted its earnings results on Tuesday, August 2nd. The pharmacy operator reported $1.32 EPS for the quarter, topping the consensus estimate of $1.30 by $0.02. CVS Health Corporation had a net margin of 2.88% and a return on equity of 15.86%. The firm earned $43.70 billion during the quarter, compared to analysts’ expectations of $44.28 billion. During the same quarter in the prior year, the firm earned $1.19 EPS. CVS Health Corporation’s quarterly revenue was up 17.6% on a year-over-year basis. Equities research analysts expect that CVS Health Corporation will post $5.86 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, November 3rd. Stockholders of record on Monday, October 24th will be paid a dividend of $0.425 per share. The ex-dividend date of this dividend is Thursday, October 20th. This represents a $1.70 annualized dividend and a dividend yield of 1.95%. CVS Health Corporation’s dividend payout ratio (DPR) is 39.08%.

Several hedge funds and other institutional investors have recently made changes to their positions in CVS. East Coast Asset Management LLC. raised its position in CVS Health Corporation by 0.3% in the second quarter. East Coast Asset Management LLC. now owns 2,431 shares of the pharmacy operator’s stock worth $233,000 after buying an additional 7 shares during the last quarter. Valley National Advisers Inc. raised its position in CVS Health Corporation by 0.5% in the second quarter. Valley National Advisers Inc. now owns 1,790 shares of the pharmacy operator’s stock worth $171,000 after buying an additional 9 shares during the last quarter. Lourd Capital LLC raised its position in CVS Health Corporation by 0.3% in the second quarter. Lourd Capital LLC now owns 3,598 shares of the pharmacy operator’s stock worth $344,000 after buying an additional 11 shares during the last quarter. Thompson Davis & CO. Inc. raised its position in CVS Health Corporation by 0.5% in the second quarter. Thompson Davis & CO. Inc. now owns 2,606 shares of the pharmacy operator’s stock worth $249,000 after buying an additional 14 shares during the last quarter. Finally, Sfmg LLC raised its position in CVS Health Corporation by 0.9% in the second quarter. Sfmg LLC now owns 2,826 shares of the pharmacy operator’s stock worth $271,000 after buying an additional 25 shares during the last quarter. Institutional investors own 80.96% of the company’s stock.

CVS Health Corporation Company Profile

CVS Health Corporation, together with its subsidiaries (CVS Health), is a pharmacy company. The Company operates through three business segments: Pharmacy Services, Retail/LTC and Corporate. The Company offers a range of products and services, such as advising patients on their medications at its CVS Pharmacy locations, introducing programs to help control costs for its clients at CVS Caremark, how care is delivered to its patients with conditions through CVS Specialty, pharmacy care for the senior community through Omnicare.

5 Day Chart for NYSE:CVS

Receive News & Stock Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related stocks with our FREE daily email newsletter.